In the past two decades, there has been a dramatic increase in the prevalence of pancreatic cysts diagnosed in US adults because of the increased frequency and better quality of cross-sectional imaging, as well as the aging of the population ( 1 -4 ). Because of the malignant transformation potential of cysts into mucinproducing adenocarcinoma, diagnostic strategies such as endoscopic ultrasound fi ne-needle aspiration and DNA-based evaluation of cyst fl uid have been used to help determine at-risk lesions ( 5 -7 ). However, despite improved recognition, more focused diagnostic strategies and increased frequency of surgical resection for proven mucin-producing pancreatic cysts, mortality rates for both pancreatic adenocarcinoma, and intraductal papillary mucinous neoplasms (IPMN)-related pancreatic adenocarcinoma have not changed ( 4,8 -10 ).
In the past two decades, there has been a dramatic increase in the prevalence of pancreatic cysts diagnosed in US adults because of the increased frequency and better quality of cross-sectional imaging, as well as the aging of the population ( 1 -4 ) . Because of the malignant transformation potential of cysts into mucinproducing adenocarcinoma, diagnostic strategies such as endoscopic ultrasound fi ne-needle aspiration and DNA-based evaluation of cyst fl uid have been used to help determine at-risk lesions ( 5 -7 ) . However, despite improved recognition, more focused diagnostic strategies and increased frequency of surgical resection for proven mucin-producing pancreatic cysts, mortality rates for both pancreatic adenocarcinoma, and intraductal papillary mucinous neoplasms (IPMN)-related pancreatic adenocarcinoma have not changed ( 4,8 -10 ) .
One reason for the lack of improvement in pancreatic adenocarcinoma mortality is likely the absence of prospective natural history data on the rate of malignant transformation of pancreatic cysts into mucin-producing adenocarcinoma. Of particular interest is whether the increasing recognition and treatment of pancreatic cystic lesions is clinically meaningful. While estimates (based on surgical series) of the malignant transformation rate have been estimated as high as a 25 % lifetime risk in patients with branchedduct IPMN, our center ' s clinical experience of evaluating and following longitudinally 100 -200 patients annually with pancreatic cystic disease overwhelmingly suggests that malignant transformation is unlikely ( 11 -15 ) .
Th e aim of this study was to determine the prevalence rate of mucin-producing adenocarcinoma in US adults with pancreatic cysts. We hypothesized a priori that based on cancer registry and US census data, malignant transformation of pancreatic cysts into mucin-producing adenocarcinoma is a rare event.
Methods
Study design . As this study was based on de-identifi ed data, institutional review board approval was not obtained. Th is was a retrospective, population-based cross-sectional study, which calculated the annual total number of a specifi c numerator (mucinproducing adenocarcinoma) over a denominator, representing the population at risk (US adults with pancreatic cysts) to obtain a prevalence rate. Given the low prevalence of both pancreatic cysts and pancreatic malignancy in patients < 40 years old, we included only adults aged 40 -84 years. Th e primary outcome was the prevalence rate of mucin-producing adenocarcinoma in US adults with pancreatic cysts. Secondary outcomes included the aforementioned prevalence rate in men and women.
Establishing the numerator . Currently, the most comprehensive national database of mucin-producing adenocarcinoma can be obtained from national Surveillance Epidemiology and End Results (SEER-18) data ( 16 ) . Th e SEER-18 database refl ects histologically confi rmed cancer registry cases collected between the years 2005 and 2009 from 18 geographic areas within the United States.
To identify the annual number of patients with mucin-producing adenocarcinoma between the ages of 40 and 84, the annual total number of patients with pancreatic malignancy was calculated by multiplying pancreatic cancer incidence rates (prevalence rates not available) from SEER 18 ( ( 16) ). Th is percentage was then multiplied by the annual number of pancreatic adenocarcinoma to determine the number of annual mucin-producing pancreatic adenocarcinomas in the United States. Finally, to establish the number of mucin-producing adenocarcinoma stratifi ed by gender, this number was multiplied by the relative rates of mucinous lesions in men and women based on the Crippa manuscript and SEER data ( 15 ) .
Establishing the denominator . Currently, no national database exists that accurately refl ects the prevalence of pancreatic cysts in the United States. US census data from 2010 was used to determine the population of adults aged 40 -84 years. ( 17 ) Th e rate of cysts in this population was determined using what was felt to be the two most scientifi cally rigorous studies published to date concerning the rate of cysts in asymptomatic patients undergoing crosssectional imaging for reasons not related to pancreatic disease. Th ese two studies also were chosen because they both had low cyst prevalence rates, and were therefore considered to provide the most conservative estimate of prevalence. Th e fi rst study found a cyst prevalence rate of 2.4 % (95 % confi dence interval (CI): 1.9 -3.0) in 2,803 consecutive patients undergoing abdominal magnetic resonance imaging at an institute of preventative medical care in Germany from December 2006 to September 2008 ( 2 ) . Th e second study found a cyst prevalence rate of 2.6 (95 % CI: 2.0 -3.2) in 2,832 consecutive patients undergoing computed tomography (CT) imaging for conditions other than known or suspected The cyst prevalence rate was determined by combining the mean cyst rate of the two most scientifi cally rigorous cross-sectional imaging studies on cyst prevalence ( 1, 2 ) .
pancreatic disease at a major US academic center ( 1 ) . For the purposes of this report, the two cyst prevalence rates (no signifi cant rate diff erence between men and women) from the Laff an and De Jong ( 1,2 ) studies were combined and then multiplied by the total population to determine the rate of cysts in adult patient in the United States.
Statistical analysis . SEER * Stat statistical soft ware (Surveillance Research Program, National Cancer Institute ( http:www. seer.cancer.gov/seerstat ), version 7.1.0) was used to access the SEER 18 data.( 16 ) Prevalence rates were calculated as a rate per 100,000. Since the exact time intervals for development of the malignancies was not known, the Poisson distribution could not be used to calculate 95 % CIs. However, because the sample size was large, a normal distribution was assumed and the formula 1.96 × √ ( r / 100,000) × (1 − ( r / 100,000)) / 100,000, where r = prevalence, was used to calculate the 95 % CI. Table 22 .2, a total of 1,137 adenocarcinomas were mucinous in origin. Th is number was then multiplied by 51.5 % , the rate relative rate of invasive mucinous lesions in women calculated from the Crippa manuscript and SEER data, to determine the fi nal count of 551 men and 586 women. Table 1 demonstrates the calculation of cyst number in the US adult population. For each age group, the US population based on the 2010 census was multiplied by the cyst prevalence rate found by taking the mean rate from the Laff an and De Jong studies stratifi ed by age ( 1, 2 ) . Th e annual crude and age-specifi c prevalence rates of pancreatic mucin-producing adenocarcinoma in 40-to 84-year-old US patients with pancreatic cysts is shown in Table 2 . As expected, the prevalence rate increased in each age group, with 80-to 84-year-old men having the highest prevalence rate at 38.6 per 100,000. Determined from data in Table 1 .
Results

Data
Th e overall prevalence rate of mucin-producing adenocarcinoma in all US adults between the ages of 40 and 84 years, irrespective of cyst presence, was 0.83 per 100,000.
Discussion
Th ese data demonstrate that the malignant transformation of pancreatic cysts into mucin-producing adenocarcinoma is a rare event in US adults, thereby lending support to our clinical observation that pancreatic cysts rarely develop into malignancy when followed longitudinally. Despite the dramatic increase in the number of pancreas cysts being detected, evaluated, and resected, no decline in either the pancreatic adenocarcinoma or IPMNrelated carcinoma mortality rate has occurred. Th ese fi ndings suggest that the vast majority of pancreatic cystic lesions do not lead to any clinically meaningful disease. Th e rising prevalence of pancreatic cysts is probably due to two factors -the increased use and improved quality of cross-sectional imaging and the aging of the population ( 11 ) . Th e fi nding of the " incidental pancreatic lesion " oft en leads to clinical and patient concern, usually prompting referral for subspecialty surgical, gastroenterology, or oncology consultation with subsequent crosssectional imaging, endoscopic ultrasound / percutaneous biopsy, and even primary surgical resection.
However, while there are certainly incidentally found mucinous lesions, such as nodular main duct IPMN, that warrant resection, the natural history of these lesions is unknown ( 7, 10 ) . Because of this, even when the lesion is well characterized, the optimal means of maximizing survival and quality of life while minimizing cost is extensively debated ( 11,18 -22 ) .
Th is study attempted to provide information on the natural history of pancreatic cysts by using a population-based cross-sectional methodology as a substitute for a prospective, longitudinal study. Th e most striking fi nding was the rarity of mucin-producing adenocarcinoma in the US adult population, given the assumed large total number of cysts. When considering the entire US adult population, and not just those with pancreatic cysts, the risk becomes minuscule.
Th is analysis is meant neither to undermine the importance of identifying and treating cystic lesions that are at high risk to harbor malignancy nor to discourage aggressive evaluation of lesions found in high-risk individuals, e.g., those with hereditary pancreatitis, Peutz -Jeghers syndrome, or familial atypical multiple mole melanoma syndrome ( 8 ) . Furthermore, patients with symptoms directly attributable to the pancreatic cystic lesion, such as those with obstructive acute pancreatitis, should usually have resection.
However, this study should be used as a caution against overly aggressive diagnosis and treatment of pancreatic cystic lesions. Simply stated, in the vast majority of patients, aggressive diagnosis using endoscopic ultrasound and fl uid DNA analysis is not warranted based on the epidemiological fi ndings.
One potential criticism of this work centers around the means by which the numerator and denominator were defi ned and its reliance on several assumptions with regard to prevalence rates.
Th e most robust US cancer registry is the SEER database, as it allows for the determination of lesions based on histological classifi cation. Although there certainly could be misclassifi cation bias with regard to histology -i.e., more than 4.1 % of adenocarcinomas actually do arise from mucin-producing cystic lesions -it is unlikely that a larger numerator would appreciably change the fi ndings of the study. In addition, because the relative percent of invasive mucin-producing adenocarcinoma stratifi ed by gender is unknown, the exact rate in men and women had to be estimated based on best available data.
With regard to the denominator, it is important to recognize that not every incidental pancreatic cyst is mucin-producing, and, as such, the rate of mucin-producing cysts undergoing malignant transformation is higher than the rate reported in this study. However, the study aimed at determining the prevalence rate of those cysts found incidentally on cross-sectional imaging undergoing transformation -this refl ects the situation in clinical practice. Furthermore, if studies with higher cyst prevalence rates had been used instead of the Laff an and De Jong rates, the prevalence rate of malignant transformation would have been even lower (see Table 3 ) . Conversely, if one used a lower rate of cyst prevalence, e.g., 0.7 % as was found in a large retrospective series evaluating pathologic, surgical, and radiographic data at a single tertiary medical center, the rate of malignant transformation would still be only 139.2 per 100,000 ( 25 ) .
We also chose to report prevalence rates rather than incidence rates for two reasons. For one, the incidence rates of incidental pancreatic cysts are not known; cross-sectional studies performed universally report prevalence rates. In addition, since pancreatic adenocarcinoma is almost a universally fatal disease, the incidence of disease on an annual basis closely approximates disease prevalence.
Acknowledging the above limitations, the current data further underscore the importance of developing a prospective national database to understand the true malignant transformation rate of mucin-producing pancreatic cysts. In the interim, clinicians need to carefully weigh these reported results in the context of 
